ST Pharm Co.,Ltd.

KOSDAQ:A237690 Stock Report

Market Cap: ₩1.8t

ST PharmLtd Valuation

Is A237690 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A237690 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A237690 (₩87000) is trading above our estimate of fair value (₩61486.55)

Significantly Below Fair Value: A237690 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A237690?

Key metric: As A237690 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A237690. This is calculated by dividing A237690's market cap by their current earnings.
What is A237690's PE Ratio?
PE Ratio80.7x
Earnings₩21.71b
Market Cap₩1.75t

Price to Earnings Ratio vs Peers

How does A237690's PE Ratio compare to its peers?

The above table shows the PE ratio for A237690 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.8x
A069620 Daewoong Pharmaceutical
16.1x17.2%₩1.5t
A185750 Chong Kun Dang Pharmaceutical
5.8x-21.8%₩1.2t
A128940 Hanmi Pharm
19.6x7.4%₩3.6t
A214370 Caregen
25.7x14.1%₩869.7b
A237690 ST PharmLtd
80.7x40.1%₩1.8t

Price-To-Earnings vs Peers: A237690 is expensive based on its Price-To-Earnings Ratio (80.7x) compared to the peer average (16.8x).

Price to Earnings Ratio vs Industry

How does A237690's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$48.50m
No more companies available in this PE range
A237690 80.7xIndustry Avg. 14.2xNo. of Companies8PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A237690 is expensive based on its Price-To-Earnings Ratio (80.7x) compared to the KR Pharmaceuticals industry average (14.6x).

Price to Earnings Ratio vs Fair Ratio

What is A237690's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A237690 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio80.7x
Fair PE Ratio31.1x

Price-To-Earnings vs Fair Ratio: A237690 is expensive based on its Price-To-Earnings Ratio (80.7x) compared to the estimated Fair Price-To-Earnings Ratio (31.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A237690 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩87,000.00
₩127,700.00
+46.8%
6.0%₩140,000.00₩112,000.00n/a10
Nov ’25₩95,700.00
₩127,700.00
+33.4%
6.0%₩140,000.00₩112,000.00n/a10
Oct ’25₩100,700.00
₩127,444.44
+26.6%
6.4%₩140,000.00₩112,000.00n/a9
Sep ’25₩115,000.00
₩123,000.00
+7.0%
9.4%₩140,000.00₩100,000.00n/a9
Aug ’25₩88,400.00
₩115,777.78
+31.0%
11.5%₩140,000.00₩100,000.00n/a9
Jul ’25₩89,800.00
₩111,333.33
+24.0%
13.0%₩140,000.00₩100,000.00n/a9
Jun ’25₩91,000.00
₩105,000.00
+15.4%
12.6%₩140,000.00₩100,000.00n/a8
May ’25₩93,400.00
₩105,555.56
+13.0%
11.9%₩140,000.00₩100,000.00n/a9
Apr ’25₩90,100.00
₩104,444.44
+15.9%
12.9%₩140,000.00₩90,000.00n/a9
Mar ’25₩63,600.00
₩104,444.44
+64.2%
12.9%₩140,000.00₩90,000.00n/a9
Feb ’25₩63,400.00
₩105,000.00
+65.6%
12.2%₩140,000.00₩90,000.00n/a10
Jan ’25₩67,800.00
₩105,000.00
+54.9%
12.2%₩140,000.00₩90,000.00n/a10
Dec ’24₩63,600.00
₩110,909.09
+74.4%
16.1%₩150,000.00₩90,000.00n/a11
Nov ’24₩68,200.00
₩113,636.36
+66.6%
14.7%₩150,000.00₩100,000.00₩95,700.0011
Oct ’24₩76,400.00
₩122,000.00
+59.7%
10.9%₩150,000.00₩110,000.00₩100,700.0010
Sep ’24₩78,700.00
₩120,000.00
+52.5%
11.8%₩150,000.00₩100,000.00₩115,000.0011
Aug ’24₩76,800.00
₩119,230.77
+55.2%
11.1%₩150,000.00₩100,000.00₩88,400.0013
Jul ’24₩76,900.00
₩120,833.33
+57.1%
10.9%₩150,000.00₩100,000.00₩89,800.0012
Jun ’24₩88,800.00
₩120,833.33
+36.1%
10.9%₩150,000.00₩100,000.00₩91,000.0012
May ’24₩79,000.00
₩121,538.46
+53.8%
11.6%₩150,000.00₩100,000.00₩93,400.0013
Apr ’24₩74,000.00
₩121,428.57
+64.1%
11.2%₩150,000.00₩100,000.00₩90,100.0014
Mar ’24₩78,400.00
₩121,250.00
+54.7%
11.4%₩150,000.00₩100,000.00₩63,600.0012
Feb ’24₩82,100.00
₩121,363.64
+47.8%
11.9%₩150,000.00₩100,000.00₩63,400.0011
Jan ’24₩87,600.00
₩125,454.55
+43.2%
11.3%₩150,000.00₩100,000.00₩67,800.0011
Dec ’23₩77,400.00
₩125,454.55
+62.1%
11.3%₩150,000.00₩100,000.00₩63,600.0011
Nov ’23₩76,100.00
₩127,272.73
+67.2%
11.5%₩150,000.00₩100,000.00₩68,200.0011

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,500.00

7D

-4.4%

1Y

79.2%

Medy-Tox

₩830.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩123,300.00

7D

-10.8%

1Y

-41.6%

J2KBIO

₩54.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,490.00

7D

-13.3%

1Y

n/a